CU Innovations Fall 2018 Newsletter

FALL 2018CU INNOVATIONS UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS BRINGING IDEAS TO NEW HEIGHTS CU ANSCHUTZ RECEIVES HISTORIC GIFT To fuel healthcare innovation and further the reputation of Anschutz Medical Campus as a world-class medical destination INSIDE THE ISSUE: Techstars Affiliate Program RAIN Therapeutics NMHIC Goes Global Re-imagining Pediatric Care

Welcome to the CU Innovations Fall 2018 Newsletter!What a momentous year it has been with nearly 200 new inventions and many new start-ups that have cumulatively raised more than $85 million in funding. We continue to advance the University of Colorado Anschutz Medical Campus Innovation Ecosystem!A myriad of accomplishments and new beginnings marked this past year which continue to acceleratethe growth, development, and vibrancy of the campus.An historic $120 million gift from The Anschutz Foundation will significantly enhance our focus oninnovations, fortifying the array of talent and resources that make the Anschutz Medical Campus aworld-class destination for healthcare and a leading institution for cutting edge scientific discoveries.CU Innovations launched the SPARK Program, in partnership with Stanford University, to bridge thetranslational gap in advancing biomedical discoveries into promising new treatments for patients. Bi-weekly SPARK sessions provide opportunity for all members of the CU Anschutz Medical Campus tolearn about commercialization and product development.Recently announced Chancellor’s Discovery & Innovation Fund (CDI Fund) will support our facultymembers and fuel research projects across the campus.We continue to expand our campus as construction has commenced for the Bioscience Building 3, partof the Fitzsimons Innovation Community. The new building allows for expansion of job opportunitiesand a further influx of talent into our already thriving innovation climate.All of our accomplishments are enabled by the support of donors like The Anschutz Foundation, ourinvestor network, and the hard work of our innovator community. We look forward to partnering withyou in the year ahead as we continue to transform the future of healthcare and biomedical research.Sincerely,Kimberly Muller, Esq.Managing Director

5 11 13CONTENTS 3 Innovation News 13 Innovation Spotlight Record Gift From The Anschutz Foundation Rain Therapeutics 5 Innovation Spotlight 15 Innovation Spotlight Medical Device Re-Imagines Pediatric Care SPARK 2018 Innovators 9 Education and Outreach 17 Partnership Leading VC Visits AMC Innovation Across Campus10 Resources 19 Partnership Funding Opportunities CU Anschutz Joins Techstars11 Innovation Spotlight 20 Innovation News NMHIC Goes Global Liason Program 20 Upcoming EventsCU Innovations brings together industry partners, entrepreneurs, PUBLISHER | EDITOR IN CHIEF CONTRIBUTORSand investors to help CU Researchers solve important problems Joleen Deisler Debra Boeldt, PhDand improve the quality of life worldwide. With expertise in patents, Trisha Kendallcopyrights and licensing, we help translate discovery into impact ART DIRECTOR | EDITOR Mimi McFaul, PsyDthrough transparent, flexible, best practice intellectual property Rolfe Bautista Amanda Penningtonmanagement services, and connect researchers at CU's Anschutz Stephanie SoMedical Campus with a variety of commercialization programs in the COPY DIRECTOR Matt Vogluniversity and the community. Cigdem Benam, PhD PRODUCTIONPartner with CU Innovations: CU Printing Services303-724-4003 | [email protected]://innovations.ucdenver.edu Fall 2018 2

INNOVATION NEWS FRO$120 MILLION TO FUEL HEALTHCARE INNOVATION AND FURTHER THE RESOURCES THAT POWER THIS WORLD-CLASS MEDICAL DESTINATION BY TRISHA KENDALLThe University of Colorado the Colorado Center for Personalized Anschutz Medical Campus Medicine, the Colorado Clinical has received a $120 million and Translational Sciences Institute,gift, the largest private philanthropic classrooms, exhibit space and more.commitment in its history, to furtherelevate its stature as one of the “We are proud partners in thecountry’s top medical destinations. development of the University of Colorado Anschutz Medical CampusThe Anschutz Foundation and its and share an ambitious vision for furtherfounder and chair, Philip Anschutz, elevating it among the country’s topmade the unprecedented commitment medical destinations,” said Mr. Anschutz.to accelerate the campus’s growth and “The campus stands as a Coloradodevelopment as one of the newest landmark and a hub of leading-edgeand most prominent academic medical research, innovation, and education –campuses in the United States, the only and, perhaps most importantly, as theone in the Rocky Mountain region, and place to go for the highest-quality healththe largest from Chicago to the West care delivered by the best minds inCoast. This gift brings The Anschutz medicine.”Foundation’s total investment in theUniversity of Colorado Anschutz In addition to funding bright minds inMedical Campus to nearly $300 million research, education and clinical care,since 2000. the campus will dedicate philanthropic funds to invest in CU Innovations to \"The campus stands as a facilitate the translation of science and Colorado landmark and a innovation into marketable products andhub of leading-edge research, services that improve lives. innovation, and education...\" “Our proud history of innovation hasThe gift will support strategic faculty led to important new discoveries,recruitment and retention, innovative and through CU Innovations, we areresearch efforts, industry partnerships capitalizing on our deeply rootedand technology transfer, and a new entrepreneurial spirit by connecting390,000-square-foot interdisciplinary University of Colorado AnschutzAnschutz Health Sciences Building. Medical Campus inventors withThe university will break ground later innovators and industry partners whothis year on the new building, which can take their breakthroughs to market,”will house faculty leaders in mental said Chancellor Don Elliman.and behavioral health including the CUDepartment of Psychiatry, as well as Contact us with your idea: [email protected] CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

OM THE ANSCHUTZ FOUNDATION

5 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

INNOVATION SPOTLIGHTMEDICAL DEVICE RE-IMAGINESPEDIATRIC CAREMULTIDICIPLINARY COLLABORATION FORGES TRIPLE ENDOSCOPY INC. BY STEPHANIE SOAt the Children’s Hospital Joel Friedlander MD and his team Colorado, a young (Robin Deterding MD, Jeremy Prager patient prepares for an MD, Emily DeBoer MD, Nurse Clintonesophagogastroduodenoscopy, or, Smith, and Respiratory Therapistmore simply, an upper endoscopy for an Krystal Mesenbrink) are the pioneersinside look of her esophagus, stomach, of this pediatric upper endoscopy,and duodenum. which minimizes the time, costs, and risks associated with the traditionalA few years ago, an upper endoscopy procedure.would involve anesthesia, hours of resttime at the hospital, and even more Dr. Friedlander described himself asrecovery at home for the sedation to “a big kid at heart.” That attitude drewfully wear off. Both child and parent him to pediatrics where he appreciateswould often miss a full day of school and the mentality of working with kids andwork to accommodate the procedure. their persevering happiness and joy. As for his interest in gastroenterology, heToday, the doctor uses a topical credited a love for food, inspired by hisnumbing spray to numb the patient’s dietician mother, and working with hisnasal passage and throat. The patient hands, inspired by his father. Pediatricslips on a pair of virtual reality video gastroenterology was then a matchgoggles to distract herself from the thin, made in heaven.flexible endoscope threading up hernose and down into her upper digestive His experience in endoscopy attract. Family members and the patient the Children’s Hospital Philadelphiacan observe as the doctor examines evolved at the Oregon Healththe lining of the organs and performs & Science University before henecessary procedures. From start to landed at the Children’s Hospitalfinish, the patient is at the hospital for Colorado’s Aerodigestive Program.approximately an hour, and she returns The multidisciplinary program, whichto school in the same day. includes specialists in anesthesiology, Fall 2018 6

otolaryngology, gastroenterology, their own role with endoscopy and doctors on protecting the intellectual pulmonology, and feeding, each physician their own scope, of property rights of their medical swallowing, and nutrition, provides varying size, rigidity, and functionality innovations, Dr. Friedlander was a different approach to medicine. to assess their patient’s associated directed to the technology transfer Rather than focusing on a specific organ system. The individuals office (now CU Innovations). Like subset of disorders, the program also have varying techniques for other university technology transfer is dedicated to the overlapping endoscopies. Laryngoscopies and offices, CU Innovations supports disorders affecting the airways and bronchoscopies can be performed faculty members in commercializing gastrointestinal tract. with a local anesthetic, but upper their invention and making scientific endoscopies require heavier and technological developments \"The long sedation. accessible to a wider audience. In Dr. Friedlander’s case, CU Innovationsanswer required Noting, and sometimes envying, consulted on a range of issues, the differences in their instruments including intellectual property rights, years of hard and techniques, Dr. Friedlander engineering connections, and wondered if his practice might be financial management. work and long improved by learning from the other subspecialties. The process began with CU nights.\" Innovations’ advice to Dr. Friedlander Nasal endoscopes have been and his team to pursue intellectual As a pediatric gastroenterologist, used for years to perform upper property rights to protect their new Dr. Friedlander’s training in other endoscopies on adults. This devices and novel ENT methods. subspecialties was limited, but technique achieves the same results This strategy involved filing a through his colleagues, he gained of sedated endoscopy but eliminates provisional United States patent exposure to more subspecialties the need for anesthesia. Could the application and a Patent Cooperation that would inform and influence nasal endoscopy, using scopes with Treaty application to protect his practice. “How can we learn features from laryngoscopes and both domestic and international from each other and take better bronchoscopes, then be adapted for intellectual property rights. From care of our patients, realizing all pediatric upper endoscopies without there, an engineering team built the the issues we have in medicine sedation? concept of the nasal endoscope into in the twenty-first century?” he reality. asked, and the program answered. The short answer was yes. Over twenty providers, including \"How can we gastroenterologists, pulmonologists, The long answer required years of otolaryngologists, anesthesiologists, hard work and long nights. learn from occupational and speech language therapists, dieticians, nurses, and With guidance from and collaboration each other and social workers, work together on with his colleagues, Dr. Friedlander treatment plans for the patients. began his research study by take repurposing a bronchoscope, smaller In addition to striving for better, more than his usual scopes and capable of better care of efficient patient care, the program’s being inserted through the nose, and collaborative and multidisciplinary using an ENT technique to insert the our patients...\" nature provided Dr. Friedlander with scope and biopsy the esophagus. the opportunity to innovative a new The bronchoscope successfully Funding through grants and an approach, the nasal endoscopy, to a reached the esophagus but was investor group, including the CURED tried-and-true procedure. never designed to explore farther Foundation, the Meister Family, into the stomach and small intestine. and venture capitalists, allowed Dr. Friedlander works closely with Because the bronchoscope literally Dr. Friedlander and his team to his team, Nurse Clinton Smith, fell short, he required an entirely new form their own company, Triple Respiratory Therapist Krystal endoscope for a full examination. Endoscopy, Inc. (TEI), to further Mesenbrink, otolaryngologist Dr. develop devices and methods to Jeremy Prager and pulmonologists Dr. Friedlander’s next challenge improve patient care. Together with Drs. Robin Deterding and Emily was “to build a camera as small as help from the venture capitalists, DeBoer. During their collaborations, the one the pulmonologists were TEI utilized a portion of their funding each specialist was found to have using with all the capabilities the gastroenterologists use.” After attending a program advising7 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

to enhance its intellectual property Ultimately, Dr. Friedlander has for the first time,” Dr. Friedlanderportfolio with additional patent filings answered his own question about said. “It demystifies the practicefor novel devices and methods multidisciplinary medicine. He of gastroenterology in a way thatdeveloped by Dr. Friedlander and and his colleagues have learned I never had the opportunity to behis team. In their goal of advancing from each other, developed new trained to do because it didn’t exist.”the inventions for uses beyond the instruments and techniques, anduniversity and research settings, TEI improved patient care in a way Have an idea for transforminghas benefited from the continued that maximizes modern technology pediatric care?support of CU Innovations and the while minimizing the pitfalls. Where Contact theinvaluable help of their investor he might have before avoided angroup. upper endoscopy due to the risks Center for Innovation: and costs of sedation, he can now Brett PetersonDr. Friedlander describes the provide patients and their familiesoperations of TEI, which includes with more complete information and [email protected], lawyers, regulatory an actual inside look using nasal Fall 2018 8advisors, engineers, and his original endoscopy.collaborators, as a “coast-to-coastteam that is helping make [the nasal “One thing I’ve started to experienceendoscopy] happen now and that in doing these scopes with familiesis the result of what CU Innovations in the room is that families get toand the TEI team taught me.” see what’s going on in their bodies

INNOVATION NEWS Words of Wisdom From Santé Ventures JOE CUNNINGHAM ADVISES CAMPUS ENTREPENEURSJoe Cunningham, MD, Managing in, which provides them with the However, the appetite of VC for Director of Santé Ventures skills to quickly identify game taking risk also changes parallel to visited the University of changing technologies with high the state of markets. For instance,Colorado Anschutz Medical Campus potential to disrupt markets. Yet, Dr. in the last several years, biotech(AMC) to learn about university Cunningham told the audience that companies were able to raise publictechnologies, share his experiences they work to identify the experts, funds by going to initial publicon venture capital (VC) and meet with not be the experts. “We want to offering (IPO) even when not havingSPARK Colorado teams. He gave have enough expertise to find the a dollar revenue. Yet, according toa public lecture on ‘Deciphering experts in the area, reach out to Dr. Cunningham this IPO window isVenture Capital’ which was facilitated key opinion leaders. Say for a 200 closing, hence making VC reluctantby CU Innovations Entrepreneur million dollar fund we would be to take broader risk in biotechin Residence and seasoned making 18 investments and out of the industry.businessperson Steve Lindseth. 18 bets you would have one or twoDuring the talk, Dr. Cunningham succeed.” Dr. Cunningham started his careeroffered pearls of wisdom to faculty as a physician, then moved to aand students on innovation, changes Not all VCs are the same. leadership role in a hospital systemin the VC landscape, and ways Some invest in seed stage which then led him to enter theto raise funds for biotechnology companies with broader appetite world of VC. Santé Ventures,startups. for risk, whereas some invest in located in Texas, is one of the stage 2 companies that have $5 leading names of the VC worldThe world of VC are perceived as a million to $50 million in revenue. as they have established a trackblack box by outsiders. Alternatively they may fund record of successful exits thanks toThey are professional investors who mergers and acquisitions of larger their calculated strategy based ongive money to startups in exchange companies. Traditionally VC filled data. They are also one of the rarefor equity in the company. They in an important capital vacuum for cases that invests across the boardcollect money from limited partners early stage technology companies ranging from Drug projects to digital(LP) generally for ten years to set that cannot access conventional healthcare.up an investment fund, then they funding mechanisms like bank loans.invest parts of this fund to various Investment criteria ofcompanies that they keep as Santé Ventures.part of their portfolio. Many of the He elucidated the investmenttimes, they not only provide cash approach of Santé which canbut also bring along their wealth partly be generalized to the restof knowledge on how to grow a of VCs. Santé invests in early-business and how to set up a team stage life sciences and healthcarefor success. A crucial element of companies and looks for exceptionalsuccess for the VC is the expert entrepreneurs or executives in theknowledge of the field they operate sense of having relevant domain9 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

experience, expertise, proven record Santé Ventures has a process for efficiency, or access. “Predictingof success, ambition and energy. creating a product commercialization the success of companies thatHowever once they decide on strategy that focuses on developing don’t have any contemporaries isinvesting, he highlighted the fact that a technology to a predetermined a very challenging task,” said Dr.their approach would be working as point of exit or acquisition of the Cunningham, however generallya team and putting a game plan in technology. This focus on the end among these would be theplace, i.e., building a true partnership goal provides a clear road map that opportunities leading to marketrather than a confrontational steers product development towards disruption yielding high returns.relationship. key value inflection points for companies funded by Santé. A crucial pearl of wisdom Dr.Something that sets Santé Ventures Cunningham shared was advisingapart from other funds is their Dr. Cunningham highlighted the founders not to be submissive but tolevel of involvement in technology importance of taking the time to find question the VC if they actually havedevelopment. Santé provides not the right partner for the company. the funds and what their vision foronly funds but more of a partnership Many of the VC will have a large say success would be. “Picking a venturebetween the firm and the scientific on the company, hence it is important capitalist can be a difficult task withteam. Strong intellectual property or for founders to find the right fit with so many firms out in the field. Themarket position is another criteria whom their vision aligns. credibility of a VC is a valuable assetthat would convince VC to invest to your startup company. Ask firmsas it would be a major factor for Another major criteria for investment for demonstrable evidence of theirthe return. A well-defined business is a clear value proposition, which fund, current portfolio, and vision formodel, with a fair and simple, means being able to solve a pressing the future” advised Dr. Cunningham.aligned incentive among investor problem either through improvingand management is another criteria. clinical outcomes, healthcare RESOURCESFUNDING OPPORTUNITIESCDIFUND The Chancellor’s Discovery Innovation Fund is a $5M fund that will provide CHANCELLOR’S DISCOVERY INNOVATION FUND tranched milestone-based grants aimed at advancing the most promising CU ANSCHUTZ MEDICAL CAMPUS therapeutics, devices, and healthcare innovations. Learn More>>> https://cdifund.secure-platform.comGGGATES GRUBSTAKE FUND The SPARK program focuses on technologies addressing unmet medical needs to STARTUP TOOLBOX bridge the “translational gap” between the lab bench and the patient. Calls for applications open early 2019. AIA Learn more>>> https://sparkcu.org The Gates Grubstake Fund focuses on accelerating basic, clinical, and translational research related to the field of regenerative medicine. Call for applications will be announced early 2019. Learn more >>> https://bit.ly/2Pmas7t Startup Toolbox is a novel platform designed to provide faculty with services and resources related to commercialization not supported by traditional funding opportunities. Grants are awarded on a rolling basis. Learn more>>> https://bit.ly/2OsSScN Colorado’s Advanced Industries Accelerator (AIA) programs promote growth and sustainability in seven key industries through innovation, commercialization, building partnersthips, and increasing access to early stage capital. Calls for applications open early 2019. Learn more>>> https://bit.ly/2ffD8OrFor more information on funding opportunities: http://bit.ly/CUInnovationsFunding Fall 2018 10

INNOVATION SPOTLIGHT 11 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

MATT VOGL TRAVELS TO CHINA TO SPEAK AT THE 2018 WORLD CONFERENCE ON VR INDUSTRYCONTRIBUTORS: MATT VOGL, MIMI MCFAUL, DEBRA BOELDT, AMANDA PENNINGTONThe number of individuals participants after Vogl spoke since Vogl discussed the NMHIC’s Tech experiencing a mental illness there were too many questions to Innovation Network (TIN) and how in the US is overwhelming, answer in the time allotted. it works as a vehicle to ensure thatand the National Mental Health mental health VR is developed in aInnovation Center (NMHIC), led The use case for VR is well beyond way that is driven by the needs andby Executive Director Matt Vogl, video games at this point. The input of providers and patients.is focused on improving mental conference focused on areashealth access and treatment through such as education, healthcare, The adoption of VR in China,innovations, such as virtual reality architecture/design, retail, firefighting, compared to the US, is staggeringly(VR). In October, the importance of and industrial training. You could different. VR is everywhere, beingVR in mental health was underscored even attend a lecture via a virtual used in schools, businesses, andwhen Vogl traveled to Nanchang, classroom developed by VIVEDU, medical settings across the country.Jiangxi Province, China, where he a company focused on education At schools across China, VR iswas invited to speak at the 2018 and mental health applications. An becoming a mainstream teachingWorld Conference on VR Industry architecture exhibit allowed visitors tool. Vogl observed schools where(WCVRI). The theme was “VR to walk through an architectural every student had a VR headset andMakes the World Better.” Nanchang building concept to make comments used it daily to learn everything from(population 16 million) shut down, or changes long before a building biology to computer programming.schools closed, and 160,000 was actually constructed. Audi VR use and content creation wasindividuals attended the conference. demoed their cars in the retail deeply integrated into the veryChinese President Xi Jinping even exhibit, and numerous healthcare basics of education. In the comingappeared in a video stating China’s demos featured things such as years, as the US moves to makecommitment to VR. anatomy instruction platforms. mental health uses of VR more mainstream, we will continue to look\"VR is becoming a mainstream to partners in China to understand teaching tool.\" the integration and scalability of VR.While speaking at WCVRI about the Beyond the conference, Vogl About NMHIC:evolving uses of VR in mental health, had the opportunity to speak at In October of 2015, the idea for theVogl shared the spotlight with tech Guangxi University of Science and National Mental Health Innovationgiants Jack Ma (CEO, Alibaba), Wei Technology in Liuzhou, and for Center was put to paper. TheSun (founder of VIVEDU), Wenchi tech employees and academics in proposal to create a home forChen (CEO of VIA), Frank Meng Chengdu. At Guangxi University, bold innovation in mental health(Chairman of Qualcomm China), and students in the university’s Virtual was submitted to the AnschutzNoble laureate Dr. George F. Smoot. Reality program discussed the state Foundation, which soon afterThere was a tremendous amount of the VR industry and barriers in generously funded the center.of interest in using VR in medicine adoption of the technology. Inand mental health. At one point, Chengdu, at the headquarters of To learn more about NMHIC visit:event organizers had to turn away VIVEDU, a subsidiary of HTC/VIVE, http://mentalhealthinnovation.org Fall 2018 12

TARGETEDCANCER THERAPYDR. ROBERT C. DOEBELE STARTS RAIN THERAPEUTICS TO TREAT LUNG CANCER BY CIGDEM BENAM PHDLung cancer is the most common mutations and subtypes as well as in non-small cell lung cancers type of cancer, accounting for environmental factors. Although (NSCLC). The company recently almost 2 million new cases each available therapeutic options successfully raised $18 million in year worldwide. In the US alone offer promising results for certain series A financing to advance its around 200,000 new patients are types, there is pressing unmet lead program, tarloxotinib, a hypoxia- diagnosed annually. It has also been medical need for various others. activated proDrug for EGFR exon 20 the leading cause of death among Rain Therapeutics, co-founded insertion mutations. cancer patients in the US, both men by Robert C Doebele, MD PhD, and women, totaling one fourth of all Associate Professor of Medicine at Our lungs are sponge-like organs, cancer deaths, more than the sum of the University of Colorado Anschutz whose main function is to take in breast, colon, prostate and ovarian Medical Campus and Director of oxygen as we breathe in, process it cancers. Unlike some other types, the Thoracic Oncology Research and send it to the rest of the body lung cancer is a broad umbrella Initiative, is developing targeted small through blood and remove carbon of disorders covering a variety of molecule therapeutics for cancer, dioxide via the same mechanism. diseases, triggered by different gene with the lead program focusing The air goes through our nose to13 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

INNOVATION SPOTLIGHTtrachea (windpipe) which splits into mutation means any change in the whether a Drug may be efficacioustwo tubes, the bronchi which then sequence of the gene. EGFR is a in patients. Dr. Doebele’s work isgoes to lungs and branches out to transmembrane receptor protein that potentially transformative in that hesmaller tubes called bronchioles, activates cell proliferation after an has found a new way to treat certainat the end of which exist small air external stimuli. It can be visualized forms of oncogene Driven cancers,sacs called alveoli. Typically the as a rope with one end inside the based on observations first made incells around bronchi, bronchioles cell and the other outside, which lung-cancer patients. And buildingor alveoli would be the first target functions like a magnet for proteins in a new company to quickly advanceof cancer, which means these cells the body to bind. However, through the discovery to clinical trials is nobecome abnormal and start to grow this genetic mutation, EGFR becomes easy task” said Bellesheim. In manyin an uncontrolled manner. When constantly active, stimulating cell cases, when brilliant scientists prefercancer cells quickly proliferate, they growth in an unregulated manner. to also run the business, they run intoform tumors and can spread to other Current therapies are mainly tyrosine a foreign world where the traditionalparts of the body. kinase inhibitors, or standard EGFR academic rules do not apply. Almost inhibitors, that block the enzymes in sine qua non for having a successful \" Dr. Doebele charge of the activation of various startup building a management proteins. However, Exon 20 mutation team, who come with the expertise, and Rain patients do not respond well to network and credibility in the eyes of these therapies as this specific investors. Dr. Doebele also affirmed Therapeutics mutation is very similar to wild-type this: “We know the science, and EGFR that exists in various other assembling a team that understands represent parts of the body. Thus, blocking the business aspect of the story has all EGFR activation pathways been instrumental to our success.” the changing creates significant side-effects. Rain Therapeutics’ lead candidate, a \"...tarloxotinib face of CU hypoxia-activated proDrug called offers a new tarloxotinib, offers a new therapeutic therapeutic Anschutz...\" opportunity for this sub-group of opportunity for patients. this sub-groupLung cancer is generally divided of patients.\"into two major types depending Dr. Doebele, an accomplishedon how they are seen under the physician scientist, is well positioned As CU Anschutz Chancellor Donmicroscope. The first group is small to observe unmet medical needs Elliman stated, “We have ancell lung cancer which covers 10 - through his clinical practice and exemplary Cancer Center, with15 % of cases and it occurs almost takes the initiative to understand brilliant scientists and cliniciansexclusively in heavy smokers. The disease models and develop pushing the boundaries of availablesecond group is non-small cell lung therapies through his bench work. therapeutics for patients. Dr. Doebelecancer (NSCLC) which covers 80 - “I have been consulting various and Rain Therapeutics represent85% of cases. This is an umbrella biotech companies and institutions, the innovation that marks the CUterm for several types of lung which has been very helpful in both Anschutz campus: faculty withcancers that behave in a similar getting to know the actors in the a deep wealth of scientific andway, hence for which generally area and building connections” said clinical knowledge, combined with asimilar therapeutic strategies are Dr. Doebele, who published earlier willingness to take an entrepreneurialadopted. Rain Therapeutics focuses findings of his research in Nature risk, leading to a direct impact thaton developing small molecule Medicine and Cancer Research improves lives.”therapies for a subgroup of NSCLC articles.patients who have an unconventional Fall 2018 14mutation in part of the sequence Brian Bellesheim, who leadsof the Epidermal Growth Factor business development at CUReceptor (EGFR), specifically Exon 20 Innovations, complimented theinsertion mutations. company cofounders for seeing the potential and successfullyThe DNA contains genetic raising Series A financing; “Thereinstructions for the development has never been greater focusand function of living things and among researchers to unravel the mechanisms that cause cancer, which is important to determine

INNOVATION SPOTLIGHT2018 INNOVATORSEVALINA BURGER, MD MELANIE JOY, PhD JEFF OLSON, MD MEDICAL DEVICE MEDICAL DEVICE MEDICAL DEVICE Professor | Team Project: Associate Professor | Team Project: Associate Professor | Team Project: Novel Cages Accomodating Novel Medical Device for Kidney Intraocular Device to PotentiateIndividual Endplate Architecture. Disease Indication. Retinal Stem Cell Transplantation in Macular Degeneration.VALERIA CANTO-SOLER, PhD MICHAEL GLODE, MD RICHARD JOHNSON, MD PHARMACEUTICAL PHARMACEUTICAL PHARMACEUTICALAssociate Professor | Team Project: Professor | Team Project: Professor | Team Project: Stem Cell-Derived 3d Retinal A Fusion-toxin for the Treatment of Targeting Sugar and Alcohol: Transplant for Dry Age-Related Macular Degeneration. Bladder Cancer. Craving and Liver Disease.15 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

SPARK Colorado aims to build SHI-LONG LU, MD, PhD DIAGNOSTIC NICHOLAS WALTER, MD DIAGNOSTICa bridge between the scientist'slab bench and the patient's Associate Professor | Team Project: Assistant Professor | Team Project:bedside by providing funding, HNKlear: A Saliva-Based Molecular Surrogate Molecular Assessment ofindustry mentorship, and a Response to TB Treatment (SMARTT-curriculum tailored for the needs Test for Head and Neck Cancer.of participating faculty and TB).researchers. It seeks to assistfaculty navigate the “valley ofdeath”, a period during which amajority of promising projects failto survive.MAX MITCHELL, MD MICHAEL CHAPMAN, MD ERNEST MOORE, PhD MEDICAL DEVICE DIAGNOSTIC Professor | Team Project: Resident ProfessorApical Cuff Implant Tool (ACIT) for Team Project: Left Ventricular Assist Device. tPA-Challenged Viscoelastometric Hemostatic Assay for Early JIM LAMBERT, PhD Identification of Fibrinolytic Coagulopathy in Trauma. MARK PETRASH, PhD MARTY ZAMORA, MD PHARMACEUTICAL PHARMACEUTICAL PHARMACEUTICAL Associate Research Professor Professor | Team Project: Professor | Team Project: Team Project: Biologic for Catarac Inhibition. Autologous CD117+ Progenitor Cell Therapy for Solid OrganA Breakthrough Therapy for Triple- Negative Breast Cancer. Transplantation.Learn how SPARK can progress your idea, visit the website: 16 sparkcu.org Fall 2018

PARTNERSHIPINNOVATIONACROSS CAMPUSParents Magazine named Children’s Hospital CO Children’s Hospital Colorado and the Center foras one of the most innovative top ten Children’s Innovation recently became the founding pediatricHospitals in the country. Cutting-edge innovations from member of the AVIA network, the nation's leadingthe Center for Innovation at Children’s Hospital CO network of healthcare organizations committed topropelled the hospital to one of the top spots. transforming care through digital innovation. Recent developments from Children’s Hospital CO: Visit to learn more about Children's Hospital: https://www.childrenscolorado.org/innovation RxRevu: creation of a pediatric module for prescription decision support Contact Children's Center for Innovation: [email protected] STAQ Pharma: development of pre-filled syringes of pediatric appropriate concentrations of medicationDevlopments in virtual monitoring systems and the necessary.” By using a virtual ICU, UCHealth canCARE Innovation Center were recently recognized in intervene significantly earlier for its inpatients.the media. Becker’s Hospital Review also recognized theModern Healthcare featured UCHealth regarding UCHealth CARE Innovation Center for providing aremote patient monitoring systems. Nurses at platform for company collaboration in healthcareUCHealth’s Virtual Health Center have the ability delivery, medical informatics and analytics,to monitor patient vitals remotely. “It's much like implementation science, clinical innovation and humana modern airplane. If you think about a pilot in a capital.modern airplane, the pilot doesn't do anything wheneverything's normal,” said Dr. Richard Zane, UCHealth's Learn more:chief innovation officer. “The computer is monitoring https://www.uchealth.org/about/innovation/thousands of data points and brings in a human when17 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

preliminary efficacy, efficacy and impact of new mobile technologies on health promotion and disease self- management. Here is a short list of some of the mobile solutions mHealth is working on today:The mHealth Impact Lab, housed in the Colorado • An app that will facilitate smoking cessation bySchool of Public Health, was founded in 2015, combining nicotine replacement therapy withwith a mission to facilitate the rapid and rigorous features from group level counseling to facilitatedevelopment, implementation, and evaluation of always on, 24-hour access to support.mobile and digital technology for health promotion anddisease prevention that address inequalities in health • An app to help persons with heart failure and theiroutcomes. caregivers to improve post hospitalization care.MHealth works with clinician researchers who seek to • A text message program to facilitate preconceptiondevelop and pilot test innovative technology-based health among American Indian and Alaska Nativesolutions using text messaging, social media, apps and Youth.sensors to improve health outcomes and clinical care;they partner with industry to create the evidence base • A text message program to support medicationfor mobile and digital solutions intended to impact refill adherence among persons with cardiovascularhealth outcomes; and they generate new knowledge illness.on approaches to using emerging technologies tofacilitate self-management of illness and promotion MHealth seeks to populate their registry with peopleof wellness among diverse populations. MHealth who are interested in being participants in pilot testsis continually adding new projects to our portfolio and larger trials to explore the impact of mobilethat broaden our focus to emerging modalities (e.g. technologies on health outcomes. People in theirVirtual Reality; Machine Learning) as well as to diverse registry will have access to a smartphone and, oncecommunities and conditions. registered, will be informed of new opportunities to participate in mobile and digital health research asMHealth is eager to share information about one of they emerge. Participants in research trials through theour latest projects: the mHealth Impact Registry. This mHealth Impact Registry will be compensated for theiris a registry of individuals who are interested in acting time for participation. It only takes a few minutes to signas participants in research studies to investigate up. If you are interested in participating, please send an e-mail to: [email protected]’s mission is to transform the current clinical I-Corps@CCTSI is a team-based short course designedand translational research and training efforts of all for faculty, staff, and students. The program guidesSchools at CU Denver and affiliated institutions into an teams through the early stages of customer discoveryinnovative, interdisciplinary, integrated, collaborative where they can test the business model hypothesescampus and hospital-wide academic home for clinical for their technology or idea.and translational sciences, scientists and trainees. Spring 2019 program in-class dates:For general questions contact: April 11, 12 and May 3, [email protected] Contact for more information and to participate: [email protected] [email protected] Fall 2018 18

PARTNERSHIPCU ANSCHUTZ BECOMES AFFILIATE PARTNERING WITH A WORLDWIDE NETWORK BY CIGDEM BENAM, PHDTechstars CU Anschutz became deserved reputation for being one ofNetwork: officially a Techstars affiliate the original inventors of the concept in September 2018. While of accelerator and successfully 4,000+ starting its own academic accelerator building a global network to Events program SPARK Colorado, the encourage entrepreneurship and 150+ university through CU Innovations is support founders in remote parts ofCountries also building strategic partnerships the world. As of 2018, the company 10,000+ with various organizations with the had accepted over 1,000 companies Mentors ultimate aim of fostering innovation into its programs with a combined 300k+ and entrepreneurship on the campus market capitalization of $9.6 billion. Alumni and help university startups flourish. CU Anschutz’ affiliation status will Techstars is a seed accelerator, enable faculty startups to have a founded in Boulder, Colorado in direct line of referral for Techstars 2006, that helps entrepreneurs programs, which are famous for their succeed. Accelerators share a competitive selection process. To common formula: providing a specific be referred to a Techstars program, curriculum based education, pairing startups will need to satisfy the teams with acclaimed industry following criteria: mentors and providing moderate funding for a fixed period of time. • A well-rounded team with Techstars is no exception. They business and technical skills operate in a cohort based setting where various teams work together • Solving real problems or in learning and improving their creating meaningful innovations products. The final stage is a demo day where potential investors would • Demonstrated early traction or be invited to showcase successful validation of core assumptions startups. • Progress on a prototype or Techstars has contributed immensely product to the entrepreneurial vibrancy and the ecosystem in Boulder. However, • Is less than 2 years old and its activities are not limited to raised no more than $1-2M Colorado; it has a global and well- For more information on the affiliation between CU Anschutz and Techstars please reach out to: [email protected] CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

INNOVATION NEWSLATEST INITIATIVE OF CU INNOVATIONS: THE LIAISON PROGRAMLeadership of the University of Colorado identifying new and promising innovations within Anschutz Medical Campus recognizes the university prior to public disclosure, ultimately innovation and commercialization of medical increasing the quality, quantity, and viability of and technological discoveries as a strategic vision. invention disclosures. Additionally, the liaisons’ In that context, CU Innovations has developed an relationship with the office will create a conduit for outreach program that focuses on the prime agents CU Innovations to connect with researchers around of innovation: the faculty. campus, increasing participation and engagement in commercialization and entrepreneurship The Liaison Program aims to create a healthy activities. two-way communication between the office and the faculty to enable an advanced culture The Liaison Program had its kick-off event on and environment of innovation on the campus. September 19, 2018 with the participation of more Identifying volunteer faculty in every department that 25 faculty from various departments and as a liaison to the office is the first step of raising divisions. awareness, better communication, and productive collaboration. For more information on the program or to volunteer please email: The Liaison network will assist CUI in understanding [email protected] the concerns and priorities of faculty as well asUPCOMING EVENTSSPARK SEMINAR SPARK SEMINARMedical Device Development Large Molecule Drug Development OverviewDecember 5, 2018 January 23, 20195:00 pm to 7:00pm 5:00 pm to 7:00pmFulginiti Pavillion Fulginiti PavillionINWORKS EXPO SPARK REQUEST FOR PROPOSALS OPENSDecember 8, 2018 Early 20192:00pm to 5:00pm https://sparkcu.orghttps://bit.ly/2DLk1qz CHANCELOR'S DISCOVERY INNOVATION FUNDDICK FOSTER AUTHOR OF CREATIVE DESTRUCTION Request for proposals opensDecember 17, 2018 https://cdifund.secure-platform.comWOMEN IN INNOVATIONJanuary 23, 2019 Fall 2018 20

Contact Us [email protected] 303-724-4003 Follow us @CUInnovations Learn More innovations.ucdenver.edu21 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

TO ADVANCE YOUR IDEAS TO FINDHEALTHCARETECHNOLOGY TO SUPPORT SCIENTIFIC DISCOVERIES Fall 2018 22

303-724-4003 | [email protected]​http://innovations.ucdenver.edu